KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Preferred Stock Liabilities (2018 - 2019)

Adaptive Biotechnologies (ADPT) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $561.9 million as the latest value for Q2 2019.

  • Quarterly Preferred Stock Liabilities changed 0.23% to $561.9 million in Q2 2019 from the year-ago period, while the trailing twelve-month figure was $561.9 million through Jun 2019, changed 0.23% year-over-year, with the annual reading at $560.9 million for FY2018, 0.08% changed from the prior year.
  • Preferred Stock Liabilities hit $561.9 million in Q2 2019 for Adaptive Biotechnologies, roughly flat from $561.2 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $561.9 million in Q2 2019 to a low of $560.7 million in Q2 2018.